Description: Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Home Page: actinogen.com.au
109 Pitt Street
Sydney,
NSW
2000
Australia
Phone:
61 2 8964 7401
Officers
| Name | Title |
|---|---|
| Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. | MD, CEO & Director |
| Mr. William Edward Souter BCom, IPAA, LLB (Adel) | Chief Financial Officer |
| Dr. Dana C. Hilt M.D. | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board |
| Mr. Michael Roberts | Head of Investor Relations & Corporate Communications |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Head of Clinical Pharmacology & Lead Physician and Depression |
| Dr. Fujun Li Ph.D. | Head of Manufacturing |
| Mr. Andrew B. Udell B.Sc., M.B.A. | Chief Commercial Officer |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 19.1939 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3535 |
| Price-to-Sales TTM: | 5.6791 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |